Literature DB >> 27300660

The difficulty of comparing drug prices between countries.

Maggie De Block1.   

Abstract

Mesh：

Year:  2016        PMID： 27300660     DOI： 10.1016/S1470-2045(16)00176-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04

2.  Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe.

Authors:  David L Carl; Kerstin N Vokinger
Journal:  Lancet Reg Health Eur       Date:  2021-02-17

3.  Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Authors:  Eirik Joakim Tranvåg; Øystein Ariansen Haaland; Bjarne Robberstad; Ole Frithjof Norheim
Journal:  JAMA Netw Open       Date:  2022-06-01

4.  Determinants of drug prices: a systematic review of comparison studies.

Authors:  Jules M Janssen Daalen; Anouk den Ambtman; Mark Van Houdenhoven; Bart J F van den Bemt
Journal:  BMJ Open       Date:  2021-07-15       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.